Showing results (241-250 of 265) with videos related to

Sort By:
Pageof 27
Cancers|February 13, 2026
Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 StudyJongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell LymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, et al.
Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.
Cancer Research and Treatment|January 3, 2023
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, et al.
The Oncologist|August 26, 2015
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck CancerKeun-Wook Lee, Youngil Koh, Sung-Bae Kim, et al.
International Journal of Hematology|September 5, 2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneHo Sup Lee, Kihyun Kim, Je-Jung Lee, et al.
Asia-Pacific Journal of Clinical Oncology|March 14, 2023
Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphomaYoon Jung Jang, Sang Moo Lim, Inki Lee, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Haematologica|October 6, 2022
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
Pageof 27